CD314 (NKG2D) antibodies, human

CD314 (NKG2D) antibodies, human

Clone: REA1228 | Dilution: 1:50
Clone REA1228 recognizes CD314 (NKG2D), a cell surface receptor of the type II transmembrane receptor NKG2 family. It is expressed on natural killer (NK) cells, CD8
+
α/β T cells, and γ/δ T cells. Though NKG2D itself possesses no intrinsic signaling capability, ligand engagement while associated to the adaptor proteins DAP10 or DAP12 induces cytolytic activation in NK cells as well as costimulation in certain T cell populations. Ligands for NKG2D are stress-inducible MHC Class I–related MICA, MICB, and UL16-binding proteins, expressed predominantly on epithelial cells and numerous carcinomas.
Additional information: Clone REA1228 displays negligible binding to Fc receptors.

Alternative names

Klrk1, KLR, NKG2D

Technical specifications

  • Antigen: CD314 (NKG2D)
  • Clone: REA1228
  • Isotype: recombinant human IgG1
  • Isotype control: REA Control (S) antibodies
  • Alternative names of antigen: Klrk1, KLR, NKG2D
  • Entrez Gene ID: 22914
  • Molecular mass of antigen [kDa]: 25
  • Distribution of antigen: NK cells, T cells
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Fixation: Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: PE, APC, PE-Vio615, PE-Vio770, Biotin
  • Selected references

    1. Maasho, K. et al. (2005)
      NKG2D is a costimulatory receptor for human naive CD8
      +
      T cells.
      J. Immunol. 174: 4480-4484
    2. Bauer, S. et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729
    3. Groh, V. et al. (2003) Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 100(16): 9452-9457
    4. Moretta, L. and Moretta, A. (2004) Unravelling natural killer function: Triggering and inhibitory human NK receptors. EMBO J. 23: 255-259
    5. Warren, H. S. (2005) The Eighth Human Leucocyte Differentiation Antigen (HLDA8) Workshop: Natural killer cell section report. Cell. Immunol. 236: 17-20
    6. Chaput, N. et al. (2013)
      Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR
      +
      NK cell levels correlate with disease outcome.
      Oncoimmunology 2(2): e23080
Product options: 10
for 30
tests
(1)
EUR 90.00
for 100
tests
(1)
EUR 220.00
for 30
tests
(1)
EUR 90.00
for 100
tests
(1)
EUR 220.00
for 30
tests
(1)
EUR 100.00
for 100
tests
(1)
EUR 240.00
for 30
tests
(1)
EUR 100.00
for 100
tests
(1)
EUR 240.00
for 30
tests
(1)
EUR 75.00
for 100
tests
(1)
EUR 185.00